POMDOCTOR LIMITED (NASDAQ: POM) is described as a leading online medical services platform for chronic diseases in China, with operations centered on an Internet hospital and a pharmaceutical supply chain. Company news provides insight into how this chronic disease-focused platform is developing its business model and responding to changes in China’s healthcare landscape.
News releases from Pomdoctor have covered topics such as the pricing, closing, and over-allotment of its initial public offering of American Depositary Shares on the Nasdaq Global Market under the ticker POM. These announcements outline details of the offering structure and the company’s access to capital through ADS issuance.
Pomdoctor’s updates also include unaudited financial results for reporting periods, where the company discusses net revenues, gross profit, segment performance for its Internet hospital and pharmaceutical supply chain, and the contribution of online pharmacy sales. In these communications, Pomdoctor has described efforts to strengthen cooperation with pharmaceutical manufacturers, expand its partner-doctor pool, and balance expansion with operational discipline.
Investors and observers using this news page can review Pomdoctor’s official announcements about its capital markets activities, financial performance, and operational focus on chronic disease management and pharmaceutical services in China. For those tracking POM stock, the news feed offers a centralized view of company-issued information related to its Internet hospital business, pharmaceutical supply chain operations, and strategic direction.
Pomdoctor (Nasdaq: POM) announced that on July 10, 2026 it received a Nasdaq Compliance Letter confirming it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1). Nasdaq determined that from June 25 to July 9, 2026 Pomdoctor’s ADSs closed at or above $1.00 for 10 consecutive business days, closing the matter. The company’s American Depositary Shares will continue trading on Nasdaq under the ticker symbol POM.
POMDOCTOR (NASDAQ:POM) outlined progress on its AI-enabled chronic disease management strategy, aiming to build a predictive, continuous and personalized healthcare ecosystem.
The company integrates AI analytics, remote patient monitoring, wearables, physician networks and healthcare payment partners, aligning with forecast growth in AI-driven chronic disease management markets through 2035.
POMDOCTOR (NASDAQ:POM) announced a strategic upgrade, repositioning as a foundational infrastructure provider for predictive healthcare data and services.
The company plans an AI-enabled ecosystem integrating wearables, real-world data, physician services and payment networks to support proactive, continuous chronic disease management in China and future international markets, including the United States.
POMDOCTOR (NASDAQ:POM) will change its ADS-to-Class A ordinary share ratio effective June 22, 2026 (U.S. Eastern Time). The ratio will move from 1 ADS representing 1/6 share to 1 ADS representing 3 shares, equivalent to a one-for-eighteen reverse ADS split.
ADSs in DRS and DTC will be automatically exchanged, with 18 existing ADSs consolidated into 1 new ADS. No fractional ADSs will be issued; the depositary will sell aggregated fractions and distribute net cash. The ADSs will keep ticker POM and adopt new CUSIP 73181R207.
POMDOCTOR (NASDAQ:POM) plans an ADS ratio change, effective on or about June 22, 2026, subject to SEC effectiveness of a post-effective amendment to Form F‑6.
The ratio will change from 1 ADS = 1/6 Class A share to 1 ADS = 3 Class A shares, effectively a 1‑for‑18 reverse ADS split, with no impact on total Class A ordinary shares.
Pomdoctor (NASDAQ:POM) reported fiscal 2025 net revenues of RMB399.9 million, up 16.7% year over year, and gross profit of RMB52.3 million, up 9.6%.
Net loss widened to RMB130.9 million, driven mainly by higher operating expenses, including IPO- and investor-relations-related professional fees, while Internet hospital revenue rose 69.3%.
The company completed a Nasdaq IPO in October 2025, raising gross proceeds of US$23.0 million.
Pomdoctor (NASDAQ: POM) announced a strategic upgrade to focus on AI + medical-grade smart wearables for full-cycle chronic disease management, aiming to build a closed-loop ecosystem of hardware, data, algorithms and services.
The company cites a global chronic disease management market CAGR of 11.7% to 2034 and highlights China’s ~180 million people with chronic conditions as a core opportunity.
Pomdoctor (NASDAQ: POM) is expanding integration of its platform with China’s national and local online medical insurance systems to broaden market reach and service capabilities across major cities. The company has supported online insurance settlements in Guangzhou for more than two years and plans expansion to Foshan in Q1 2026 and other Greater Bay Area and regional centers.
The initiative aims to enable online consultations, digital prescriptions, near-real-time insurance reimbursement, and home delivery of medicines via the mobile app and WeChat mini-program.
POMDOCTOR LIMITED (NASDAQ: POM) received a Nasdaq Deficiency Letter dated Jan 29, 2026, reporting the ADS closing bid price was below the required $1.00 minimum for 33 consecutive business days. The letter currently does not affect listing or trading.
The company has a 180-calendar-day compliance period ending July 28, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days; Nasdaq may grant additional time at its discretion.
Pomdoctor (NASDAQ: POM) said it is strengthening strategic collaborations with multiple domestic pharmaceutical companies to accelerate growth of its internet hospital business and enhance profitability. The company reported it has entered into sales and purchase agreements with several listed drug makers to supply innovative and patented products to its platforms, with entitlement to purchase discounts, rebates, and sales incentives tied to agreed sales targets. The release cites a fast-growing market backdrop: online drug sales in China rose to RMB 71.8 billion (≈US$10.3 billion) in 2024 with a 39.4% CAGR since 2020, which Pomdoctor says supports expansion of its nationwide internet hospital operations.